china novartis institutes for biomedical research brochure · collaborated with pudong ciq to...

At the Forefront of Drug DiscoveryChina Novartis Institutes for BioMedical Research

在创新药物研发的最前沿诺华（中国）生物医学研究中心

2 · China Novartis Institutes for BioMedical Research

China Novartis Institutes for BioMedical Research (CNIBR) is part of the Novartis global R&D network. The Novartis Shanghai R&D center opened in 2007 as the first integrated R&D center and the largest among MNCs in China.

Over the years, CNIBR has developed itself into a base for NIBR in the Asia Pacific region, lending its expertise on drug discovery to countries and regions such as South Korea, Japan and Taiwan. In its home base, CNIBR is positioned as a leader of the innovation hub and collaboration network in the local life science community in the Zhangjiang Hi-Tech Park in Pudong New Area and the city of Shanghai.

Novartis currently has about 500 R&D scientists in Shanghai and has built multiple platforms for innovative drug discovery. As a long-term commitment to China and the Chinese patients, Novartis is investing USD 1 billion to build an R&D campus in Shanghai. The new campus is located next to Shanghai Tech University and is approaching the completion of Phase I of 7 buildings including 2 world-class research lab buildings.

A LONG-TERM COMMITMENT TO CHINA

The first integrated R&D center and the largest among MNCs in China while serving as the NIBR base in the Asia Pacific

诺华(中国)生物医学研究中心 · 3

诺华（中国）生物医学研究中心（CNIBR）是诺华全球药物研发网络的一部分。

2007 年，新成立的诺华上海研发中心正式投入运营，成为跨国医药健康企业在华

建立的首家、也是规模最大的综合性研发中心。

通过多年发展，研发中心成为诺华生物医学研究中心（NIBR）在亚太地区的重要

基地，依托自身在新药研发领域的强大实力，通过各种形式的合作与交流惠及包括

韩国、日本、台湾在内的多个国家和地区的医药研发。诺华在上海浦东新区张江高

科技园区建立研发中心，旨在通过与本土生命科学研究机构广泛开展合作，扎根上

海，引领区域性创新新药研发。

目前，诺华在上海拥有 500 多名科研人员，建立了完整的创新药物研发平台。诺华

投资 10 亿美元在上海打造全新的研发园区，实践对中国及中国病患的长期承诺。

新园区毗邻上海科技大学，即将完成的一期建设项目有七幢建筑，其中包括两幢世

界一流的科研实验楼。

引领创新药物研发

跨国医药健康企业中

首家、也是规模最大

的综合性研发中心，

同时成为诺华生物医

学研究中心辐射、惠

及亚太地区医药研发

的重要基地


Innovation is at the core of Novartis values. Taking Novartis’ unique research strategy of “Focus on Patients, Follow the Science”, CNIBR has established two major drug discovery programs:

• Cancers prevalent in China and Asia, including lung cancer, liver cancer, gastric cancer, and nasopharyngeal carcinoma

• Liver diseases, including chronic HBV infection, non-alcoholic steatohepatitis (NASH), liver fibrosis and cirrhosis

CNIBR has established a full set of capabilities from genomics research, disease biology, drug discovery and pharmacology, to translational medicine, and has in-house expertise in both small molecule and biologics drug discovery. CNIBR is also known for its cutting-edge epigenetics research for novel target discovery in cancer, aging and regenerative medicine.

AT THE FOREFRONT OF DRUG DISCOVERY

“Our mission is to discover breakthrough medicine and contribute to curing diseases prevalent in China and the world. We’ve been introducing to China advanced drug discovery technologies, developing young talent in China, and establishing collaborations with local universities, research institutes and hospitals.”

En Li, Head, CNIBR

“Focus on Patients, Follow the Science”


创新是诺华的核心价值观。在诺华公司独特的药物研发战略的指导下，即“以患者

为本、以科学为基础 ”，诺华在上海的研发中心的新药研发项目主要集中在以下两

个研究领域：

• 中国及亚洲地区的高发癌症，包括肺癌、肝癌、胃癌及鼻咽癌

• 肝病研究，包括慢性肝炎、非酒精性脂肪性肝病、肝纤维化和肝硬化

研发中心拥有小分子和生物制剂两类新药的自主研发能力，建立了一整套核心研发

实力，涵盖基因组学研究、疾病生物学、新药研发及转化医学。

此外，研发中心因将世界领先的表观遗传学研究与创新药物研发结合而知名，得以

针对包括癌症、老年性疾病、再生医学等领域来发现新的治疗靶点。

引领创新药物研发

研发突破性新药、对治疗中国和亚洲地区高发疾病作出贡献是我们的使命。我们

将先进的药物研发技术引进中国，致力于培养中国新一代人才，并与中国本土大学、

科研机构和医院建立合作关系。”

李恩，诺华（中国）生物医学研究中心总经理

“

“ 以患者为本、以科学

为基础”


In 2007-2014, CNIBR scientists have delivered many novel drug targets into the global pipeline including bringing a number of first-in-class drug candidates targeting cancer and liver disease into pre-clinical phase. Currently the Center is running 15 drug discovery projects at different stages.

Combining innovative drug discovery with translational medicine capability, CNIBR has achieved the first successful Proof of Concept (PoC) for lung cancer (a cMET kinase inhibitor) in 2013, and obtained a number of clinical trial approvals (CTA) from China FDA (CFDA) for multiple drug candidates including the latest 5 compounds for lung cancer cluster trials in 2014.

CNIBR has built win-win collaboration with Chinese universities, research and clinic institutes in areas such as cancer epigenetics, stem cell and regeneration, genomics and bioinformatics, and synthetic chemistry. The Center has also been working closely with more than 40 local biotech and contract research organizations (CRO).

Major collaborators

OUR ACHIEVEMENTS AND PROGRESS IN CHINA

• Ruijin Hospital of Shanghai Jiaotong University

• Zhongshan Hospital, Guangzhou• Xijing Hospital, Xi’an• Huaxi Hospital, Chengdu• PUMCH, Beijing

• Fudan University • Tongji University• Shanghai Tech University • Shanghai Institute of Materia Medica • Shanghai Institute of Biochemistry

and Cell Biology (Chinese Academy of Science)

The Center has advanced lung cancer drugs to clinics and built a strong pipeline


2007 至 2014，研发中心的科研人员为诺华全球研发产品线提供了许多新药靶点，

包括将多个针对癌症和肝病的新型候选药物推进至临床前试验阶段。目前，研发中

心有 15 个处于不同研发阶段的新药研究项目。

研发中心将创新药物研发与转化医学科研能力结合，其针对肺癌的 c-Met 激酶抑

制剂已于 2013 年成功通过了“概念验证”，并有多个候选药物获中国国家药监局

批准进入临床试验，其中就包括 2014 年中国肺癌靶向组群临床试验的 5 个药物化

合物。

研发中心和中国本土大学、科研及临床研究机构建立了广泛的双赢合作关系，携手

共同研究癌症表观遗传学、干细胞和再生、基因组学、生物信息学以及合成化学等

领域。此外，研发中心和 40 多家本土生物科技及外包服务公司合作推进药物研发

项目。

主要合作伙伴包括：

• 复旦大学

• 同济大学

• 上海科技大学

• 上海药物研究所

• 中国科学院上海生物化学和细胞生物学研究所

创新研发取得积极成果

• 上海交通大学附属瑞金医院

• 广州中山医院

• 西安西京医院

• 成都华西医院

• 北京协和医院

研发中心将治疗肺癌

新药推入临床阶段并

建立了强劲的研发产

品线


Novartis has devoted a lot of resources to training young talent in drug R&D in China. CNIBR research teams consist of both Chinese scientists who have returned from abroad and graduates from top-tier universities, medical schools, and research institutes in China.

In developing local young talent, CNIBR has established a number of training programs including the Research Fellow Program for Ph.D. graduates interested in drug discovery, the CNIBR R&D Apprentice Program for Bachelor or Master graduates to start a career in biomedical research, and the Novartis Young Explorer Program (a summer internship program for undergraduate students) to inspire young students. CNIBR is also the four-time host of the regional selection for the Novartis International BioCamp. In addition, CNIBR provides continuous learning in science through a robust scientific learning program tailored to the various learning needs.

DEVELOPING YOUNG TALENT FOR THE FUTURE

Talent is key to our future success


诺华投入大量资源培养中国新一代药物研发人才。研发中心的研发团队由海外归国

科学家以及国内顶尖高校、医学院和研究所毕业的科研人才组成。

为了培养本土青年人才，研发中心设立了一系列人才培训项目，包括面向对新药研

发有志趣的博士毕业生开展的“诺华研发博士后项目”，为本科及硕士人才提供生

物医药领域职业发展机会的“诺华研发培训生项目”，以及针对大学本科生、旨在

激励并吸引青年人才的暑期实习生 “诺华青年创想家” 项目。同时，研发中心先

后四次举办诺华国际生物科技菁英训练营中国区预选活动。此外，研发中心也通过

强有力的科研培训项目支持员工在科研知识方面不断深造，满足不同层次的学习需

求。

放眼未来培养新一代人才

人才是我们未来成功

的关键


Over the years, CNIBR has built strong partnerships with government to best support R&D innovation. In 2014, Shanghai government set up the goal of transforming the city into a “global hub of technological innovation” and made it a top priority for Shanghai in 2015. Shanghai government conducted studies and panel discussions with companies in various industries. CNIBR representing multinational healthcare companies was invited to participate in those discussions. We shared our experience and ideas on building a world-class R&D hub in Shanghai. In the past several years, we collaborated with Pudong CIQ to improve the import and export of research samples and reagents – a critical bottleneck for R&D in China. To recognize our contribution, CNIBR was selected as one of the Top 10 Best-Practice Corporate Headquarters in Pudong.

The Novartis Campus Shanghai will be the third largest R&D center for Novartis and is located in the most active academic center in Shanghai surrounded by top research institutes including Shanghai Tech University, Shanghai Institute of Materia Medica, Shanghai University of Traditional Chinese Medicine, School of Pharmacy of Fudan University, and National Protein Science Center. We look forward to more active collaboration in biomedical research with these institutes to advance R&D innovation in China.

AN EMERGING WORLD-CLASS R&D HUB IN PUDONG

The Novartis Campus Shanghai will be the third largest pharmaceutical R&D center for Novartis


数年来，诺华在上海的研发中心与政府建立了良好的合作关系，力求促进新药研发

的创新。2014 年，上海加快建设“具全球影响力的科技创新中心”，并将此列为

2015 年政府一号课题。政府各部门与多个行业开展调研及座谈会。诺华中国生物

医学研究中心作为跨国医药健康企业代表受邀参与相关调研讨论，就如何在沪建立

世界一流的创新研发中心分享经验和建议。自成立以来，研发中心与浦东检验检疫

局合作推进科研样品和试剂进出口程序的优化，突破制约在本土开展研发活动的瓶

颈。研发中心的贡献获得政府高度认可，入选“浦东总部经济十大经典样本”。

新建成的诺华上海园区将成为诺华全球第三大研发中心。新园区地处上海学术与创

新最活跃地区，与包括上海科技大学、中科院上海药物研究所、上海中医药大学、

复旦大学药学院、国家蛋白质科学中心等顶尖的研究机构为邻。诺华将进一步加强

与这些研究机构在生物医药方面的合作以共同推进创新药物的研发。

世界一流的新药研发基地在浦东崛起

新建成的诺华上海研

发园区将成为诺华全

球第三大研发中心


The greatest satisfaction for Novartis scientists and business professionals is to contribute to improving the quality of life for patients and to serve the community.

Novartis associates take social responsibility at heart. In 2013, a group of associates initiated the NovaStar Program with a focus on helping the kids in poor families in the remote region of Liangshan Mountains in Sichuan Province to have access to healthy meals and primary education.

Our associates are also active in promoting "Be Healthy" as a general concept by running a number of social and sports clubs. In addition to the popular sports activities such as soccer, badminton, basketball and table tennis, there are also groups practicing Marathon, Taichi and Yoga.

KEEPING PATIENTS AND COMMUNITIES AT HEART

The greatest satisfaction for Novartis associates is to serve patients and communities


对诺华的科研及商业运营人员来说，最引以为傲的就是能够为改善病患的生活质量

作出贡献并回馈社会。

诺华的员工铭记自身的社会责任，投身公益项目。2013 年，由员工自主发起的“诺

星计划”启动，为四川省大凉山地区的贫困儿童提供健康午餐和基础教育。

此外，员工积极响应公司“Be Healthy”理念，组织了一系列休闲及体育俱乐部，

除了积极开展足球、羽毛球、篮球及乒乓球等体育活动外，还热情参与马拉松、太极、

瑜伽等兴趣小组。

心系病患和社会责任

诺华员工最大的满足

在于服务病患、回馈

社会


诺华上海园区结合东西方建筑精髓和创新理念，采用国际先进质量标准，力求打造

真正世界一流的研发环境。在统一的总体规划设计理念下，园区每幢楼由国内及国

际著名设计师分别设计建造，力求创造一个促进创新与合作的园区环境。一期工程

预计 2015 年完工，为 1,200 名诺华员工提供实验、办公场所，全期建成后共可容

纳 2,500 名员工。

诺华上海园区

The Campus merges the best of eastern and western attributes and adopts international standards. With the integrated master plan and a number of internationally renowned architects joining forces in the project, the state-of-the-art Campus is designed to foster innovation and collaboration. Phase I will be completed in 2015 with a capacity for 1,200 associates and the Campus will accommodate 2,500 associates once fully completed.

Novartis Campus Shanghai

Contact

China Novartis Institutes for BioMedical Research No. 4218 Jinke Road, Zhangjiang Hi-Tech Park, PudongShanghai 201203China

www.nibr.com

china novartis institutes for biomedical research brochure · collaborated with pudong ciq to...

Documents